Studies: One Dose of "Psilocybin" from Magic Mushrooms Relieves Depression in 80% of Cancer Patients

New studies from NYU and John Hopkins University show the effectiveness of psilocybin in treating depression and anxiety of cancer patients. 

Studies: One Dose of "Psilocybin" from Magic Mushrooms Relieves Depression in 80% of Cancer Patients


The largest studies to date, by arguably the most respected institutions up to this point, show that psilocybin, a compound within "magic mushrooms", can be effective in treating depression and anxiety in cancer patients. 

The studies were carried out on 29 patients by researchers at New York University (NYU) and on 51 patients at Johns Hopkins University.

Notably, up to 40% of all cancer patients are afflicted by psychological issues related to their illness.

Around 80% of the cancer patients in the studies got noticeably better after just one dose. And they sustained the psychological gains they made for up to seven months, with few minor side effects. Patients reported improvements in their quality of life, having more energy, going out more and having better relationships with family members. 

Interestingly, those who had a stronger trip reported the strongest gains in alleviating their depression and anxiety.

A number of authorities in psychiatry and addiction medicine expressed their support for the work. These include Dr. Jeffrey Lieberman, a former president of the American Psychiatric Association and Dr. Daniel Shalev from the New York State Psychiatric Institute, who wrote that the studies are ”a model for revisiting criminalized compounds of interest in a safe, ethical way.” 

The studies were also reviewed by regulators and were described by the New York Times as "most meticulous" to date.

The lead author of the Johns Hopkins study, psychiatrist Dr. Roland Griffiths, was optimistic on the possibilities of the new treatment, likening it to a groundbreaking surgery rather than the painstaking work to make feel people better used by traditional psychiatric approaches.  

“I really don’t think we have any models in psychiatry that look like” the effects demonstrated in the two trials, said Griffiths. “Something occurs and it’s repaired and it’s better going forward … very plausibly for more than six months,” he added. “In that sense it’s a new model.”

One of the participants in the study, Sherry Marcy, described the changes in how she felt this way: 

"The cloud of doom seemed to just lift… I got back in touch with my family and kids, and my wonder at life," said Marcy, whose been battling cancer from 2010. "Before, I was sitting alone at home, and I couldn't move … This study made a huge difference, and it's persisted."

Psilocybin-containing "magic mushrooms". Credit: Getty Images.

The particulars of both studies involved randomly offering patients either psilocybin or a placebo at the first session, and then giving them the opposite treatment seven weeks later. This way all participants eventually took psilocybin. In both studies, the success rate of psilocybin versus the placebo was very clear, with 83% getting better on psilocybin and only 14% on the placebo in the NYU study. 

Psilocybin, of course, have been banned in the U.S. for over 40 years. While they were allowed to use it for their studies, the scientists warn against self-medicating depression by taking "magic mushrooms". They caution that professionals are needed to control the dosage and provide a supportive environment in which to experience the drug's effects. The psilocybin therapy may also not be appropriate for people with schizophrenia or young adults.

To move forward in this field, Dr. Shalev and Dr. Lieberman see a need to loosen research restrictions, because "there is much potential for new scientific insights and clinical applications.” Ideally, the next step would be a trial with a larger sample, perhaps across several centers with hundreds of subjects. 

Not everyone is on board. Dr. William Breitbart, chairman of the psychiatry department at the Memorial Sloan-Kettering Cancer Center expressed his reservations about the use of cancer patients for the study.

“Medical marijuana got its foot in the door by making the appeal that ‘cancer patients are suffering, they’re near death, so for compassionate purposes, let’s make it available,’ ” he said. “And then you’re able to extend this drug to other purposes.” 

The positive effect of psilocybin on depression was also demonstrated by studies earlier this year.

The current studies are published in the Journal of Psychopharmacology, with the NYU study available here and the John Hopkins study here.

Cover photo credit: Langone Medical Center/New York University. 

Golden blood: The rarest blood in the world

We explore the history of blood types and how they are classified to find out what makes the Rh-null type important to science and dangerous for those who live with it.

What is the rarest blood type?

Abid Katib/Getty Images
Surprising Science
  • Fewer than 50 people worldwide have 'golden blood' — or Rh-null.
  • Blood is considered Rh-null if it lacks all of the 61 possible antigens in the Rh system.
  • It's also very dangerous to live with this blood type, as so few people have it.
Keep reading Show less

Modern society is as unequal as 14th century Europe

As bad as this sounds, a new essay suggests that we live in a surprisingly egalitarian age.

"Philosophy Presenting the Seven Liberal Arts to Boethius"

Getty Open Content
Politics & Current Affairs
  • A new essay depicts 700 years of economic inequality in Europe.
  • The only stretch of time more egalitarian than today was the period between 1350 to approximately the year 1700.
  • Data suggest that, without intervention, inequality does not decrease on its own.
Keep reading Show less

You are suffering from “tab overload”

Our love-hate relationship with browser tabs drives all of us crazy. There is a solution.

Photo by Anna Shvets from Pexels
Technology & Innovation
  • A new study suggests that tabs can cause people to be flustered as they try to keep track of every website.
  • The reason is that tabs are unable to properly organize information.
  • The researchers are plugging a browser extension that aims to fix the problem.
Keep reading Show less
Personal Growth

Epicurus and the atheist's guide to happiness

Seek pleasure and avoid pain. Why make it more complicated?

Quantcast